Form 4: TriSalus Life Sciences Director David Matlin Granted 15,000 Stock Options

TriSalus Life Sciences, Inc. Director David J. Matlin was granted 15,000 stock options with an exercise price of $5.5, vesting over one year or upon the next annual stockholder meeting.

Summary

• David J. Matlin, a Director of TriSalus Life Sciences, Inc. (TLSI), was granted 15,000 Director Stock Options.
• The transaction date for this grant was June 12, 2025.
• The exercise price for these options is $5.5 per share.
• The options are set to fully vest on the one-year anniversary of the grant date (June 12, 2025), or in any case, on the date of the Issuer's next annual stockholder meeting, contingent on Mr. Matlin's continued service.
• The expiration date for these options is June 11, 2035.
• Following this reported transaction, Mr. Matlin beneficially owns 65,000 derivative securities.

Sentiment

Score: 6

Explanation: Slightly positive, as it indicates standard corporate governance practices and aligns director incentives with shareholder interests, without revealing any negative operational or financial news.

Positives

• The grant of stock options to a director aligns the director's financial interests with those of the shareholders, encouraging long-term value creation.
• The vesting schedule, tied to continued service, incentivizes the director's ongoing commitment to the company.

Future Outlook

The granted stock options are scheduled to fully vest on the one-year anniversary of the grant date (June 12, 2025), or earlier, on the date of the Issuer's next annual stockholder meeting, provided the reporting person continues their service with the Issuer.

Industry Context

The granting of stock options to directors is a common practice in the life sciences and broader corporate sectors. It serves as a form of equity compensation designed to attract and retain qualified board members, aligning their interests with long-term shareholder value creation. This specific filing indicates a routine compensation event for a director at TriSalus Life Sciences, Inc.

Corporate Governance

Related Party Transactions

• The grant of 15,000 Director Stock Options to David J. Matlin, a director of TriSalus Life Sciences, Inc., constitutes a transaction with a related party.

Stakeholder Impact

• Shareholders: The grant of options to a director aims to align the director's interests with shareholder value creation, potentially leading to better long-term performance.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The granted options will vest on June 12, 2025, or at the Issuer's next annual stockholder meeting, subject to continued service.

Key Dates

Keywords

TriSalus Life Sciences, TLSI, David J. Matlin, Director Stock Option, SEC Form 4, Insider Transaction, Equity Compensation, Stock Grant, Vesting Schedule